News

  • 17 September 2018

    Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study.

  • 17 September 2018

    Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Direct Sodium Removal (“DSR”) therapy proof of concept study in pigs.

  • 5 September 2018

    Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 13/319597. The allowed claims cover the optimal format for TCR-based T cell redirectors and will provide broad protection for the Company’s novel ImmTAC platform. The grant of this U.S. patent will complete broad patent protection for the ImmTAC platform in the US and adds to equivalent patent protection already obtained in other major territories including Europe and China. ImmTAC molecules are the first T cell redirectors to have demonstrated a durable response and robust overall survival rate in patients with solid tumours.  

  • 3 September 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its second pre-planned data review meeting and recommended the continuation of the Company’s trial without protocol amendment. This second review was based on data collected from 77 randomized patients including at least 60 patients who have completed their week 6 visit. The Company expects interim efficacy results in Fall 2018 and final results in the first half of 2019. 

  • 27 August 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a first-in-human study of its investigational new chemical entity SNA-125, a JAK3/TrkA inhibitor being evaluated as a first-in-class topically administered medication to treat mild-to-moderate psoriasis.